Hyderabad pediatrician Dr Sivaranjani Santosh has helped reduce the annual cost of a rare disease medicine from as much as ₹9 crore to ₹2.5 lakh per child. Seven Indian children will receive a year’s supply of the medicine free of cost from November 30, 2026, following an international collaboration
HYDERABAD: A Hyderabad-based pediatrician has helped make an expensive rare disease medicine affordable for seven Indian children. Dr Sivaranjani Santosh worked with international healthcare organisations to secure a low-cost version of tiratricol, a medicine used to manage Allan-Herndon-Dudley syndrome (AHDS).
The initiative reduced the estimated annual cost from ₹4.68 crore to ₹9 crore for commercial versions to approximately ₹2.5 lakh per child for a specially compounded formulation. The seven families will receive the medicine free of charge through donations and international support.
What Is Allan-Herndon-Dudley Syndrome?
Allan-Herndon-Dudley syndrome, also known as MCT8 deficiency, is a rare genetic disorder. It affects the body’s ability to transport thyroid hormones into brain cells. The condition can cause severe developmental delays, muscle weakness, movement difficulties and intellectual disabilities. It can also affect the heart and other organs. Doctors use tiratricol to manage the effects of abnormal thyroid hormone levels. However, its high international price makes treatment difficult for many families.
Also Read:
Burjeel Medical City introduces Gulf’s first chronic sinusitis treatment given twice yearly
How a Mother’s Plea Sparked the Initiative
The campaign began when Pavitra Sirolkar struggled to arrange treatment for her son Arav, who has AHDS. Importing a month’s supply of tiratricol from Germany cost the family approximately ₹12 lakh to ₹13 lakh. Dr Sivaranjani sought alternatives and appealed for support through social media. She then worked with K.M. Gopakumar of Access to Medicines India.
The Netherlands-based Pharmaceutical Accountability Foundation joined the initiative. Transvaal Pharmacy in The Hague prepared a specially compounded version of tiratricol at a much lower cost.
Seven Children to Receive Free Medicine
The initiative has arranged a year’s supply of tiratricol for seven children. The total cost is approximately ₹15 lakh. Dr Sivaranjani raised around ₹6.09 lakh in India. The Pharmaceutical Accountability Foundation helped arrange the remaining funds in the Netherlands.
On November 30, families of two children will receive medicine in Hyderabad. Five other families will receive their supplies in Bengaluru.
The medicine will arrive in two batches because the compounded formulation has a six-month shelf life. Families have secured individual import permissions for the treatment. Deccan Chronicle
Doctor Calls for Affordable Drug Production in India
Dr Sivaranjani now wants the Indian government to support local compounding of tiratricol under the National Policy for Rare Diseases.
She believes domestic preparation could reduce costs further and make the treatment accessible to more children. The current initiative provides relief to seven families. However, wider access will require sustainable production, regulatory approval and continued medical supervision.
Impact to Expect
The initiative could encourage new efforts to improve access to rare disease medicines in India. It also highlights how international partnerships can reduce treatment costs.
For affected families, affordable medicines could ease financial pressure and support continued medical care. The case may also strengthen calls for domestic production of expensive treatments for rare genetic disorders.
